Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | AXL | P30530 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15553028 | 0.82 | MET (0.51) | METAXLBRD4RETKIT | |
| SCHEMBL29814288 | 0.80 | AXL (0.39) | METAXLBRD4RETKIT | |
| SCHEMBL17230362 | 0.80 | AXL (0.39) | METAXLBRD4RETKIT | |
| SCHEMBL17222173 | 0.79 | AXL (0.40) | METAXLBRD4ROCK2CYP3A4 | |
| SCHEMBL15541495 | 0.79 | AXL (0.36) | METAXLROCK2CYP3A4RET | |
| SCHEMBL9905781 | 0.78 | BRAF (0.50) | METAXLBRD4ROCK2RET | |
| SCHEMBL15555430 | 0.77 | AXL (0.35) | METAXLBRD4ROCK2CYP3A4 | |
| SCHEMBL15554272 | 0.77 | AXL (0.39) | METAXLBRD4ROCK2CYP3A4 | |
| SCHEMBL2879901 | 0.76 | MET (0.50) | METAXLROCK2CYP3A4RET | |
| SCHEMBL2884105 | 0.75 | MET (0.44) | METAXLROCK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617257-B2 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2017-04-11 | — | — | US | claimed |
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2015-11-05 | — | — | US | claimed |
| EP-2867223-B1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-05 | — | — | EP | disclosed |
| US-9617257-B2 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2017-04-11 | — | — | US | disclosed |
| US-9617257-B2 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2017-04-11 | — | — | US | disclosed |
| US-9617257-B2 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2017-04-11 | — | — | US | disclosed |
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2015-11-05 | — | — | US | disclosed |
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2015-11-05 | — | — | US | disclosed |
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2015-11-05 | — | — | US | disclosed |
| EP-2867223-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Betta Pharmaceuticals Co., Ltd. (CN) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014000713-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INCORPORATION (CN) | 2014-01-03 | — | — | WO | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1562935-B1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1562935-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | MET, ABL1, ROS1 | MET 1/4885AXL 172/4885BRD4 824/4885 |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | MET 1035/4885AXL 2231/4885BRD4 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.